Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Enhancement of bone morphogenetic protein-2-induced new bone formation in mice by the phosphodiesterase inhibitor pentoxifylline
Autore:
Horiuchi, H; Saito, N; Kinoshita, T; Wakabayashi, S; Tsutsumimoto, T; Takaoka, K;
Indirizzi:
Shinshu Univ, Sch Med, Dept Orthoped Surg, Matsumoto, Nagano 390, Japan Shinshu Univ Matsumoto Nagano Japan 390 urg, Matsumoto, Nagano 390, Japan
Titolo Testata:
BONE
fascicolo: 3, volume: 28, anno: 2001,
pagine: 290 - 294
SICI:
8756-3282(200103)28:3<290:EOBMPN>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; SPINAL-FUSION; TNF-ALPHA; EXPRESSION; PROTEIN; MOUSE; INDUCTION; RECEPTORS; MONOCYTES;
Keywords:
bone morphogenetic protein (BMP); ectopic bone formation; pentoxifylline; inhibitor of phosphodiesterases (PDEs);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Horiuchi, H Shinshu Univ, Sch Med, Dept Orthoped Surg, 3-1-1 Asahi, Matsumoto, Nagano 390, Japan Shinshu Univ 3-1-1 Asahi Matsumoto Nagano Japan 390 390, Japan
Citazione:
H. Horiuchi et al., "Enhancement of bone morphogenetic protein-2-induced new bone formation in mice by the phosphodiesterase inhibitor pentoxifylline", BONE, 28(3), 2001, pp. 290-294

Abstract

Porous collagen disks (6 mm diameter, 1 mm thickness) were impregnated with recombinant human bone morphogenetic protein-2 (rhBMP-2) (5 mug/disk) andimplanted onto the bark muscles of mice. Pentoxifylline (PTX), which is a methylxanthine-derived inhibitor of phosphodiesterases (PDEs), or vehicle, was injected (5, 25, 50, 100, 200, and 300 mg/kg body weight/day) into the mice subcutaneously once a day for 3 weeks from the day of implantation of the bone morphogenetic protein (BMP)-laden disks. The rhBMP-2-induced ectopic ossicles were harvested and examined using radiographic, histological, and biochemical methods to determine size, bone quality, and calcium content. When compared with controls, ossicles from mice treated with >50 mg/kg per day of PTX were significantly larger in size and had a greater calcium content. However, no differences were noted in mice treated with lower doses (5 and 25 mg/kg per day) of PTX. The temporal sequence of the bone-forming process was unchanged by PTX based on histological examination. The histology of the ossicles front high- and low-dose PTX-treated mice was essentially identical to that observed in the control mice. These experimental results indicate that PTX enhanced the bone-inducing capacity of BMP-2. The underlying mechanism of action most likely involves the inhibition of intracellular phosphodiesterases and a resulting elevation of the intracellular content of cyclic nucleotides, Further studies are warranted to understand how BMP-induced bone formation is pharmacologically modified by PTX. (Bone 28:290-294; 2001) (C) 2001 by Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 10:24:20